Reference

Aqueous high-performance size-exclusion chromatographic assay for high-molecular-weight impurities in ceftiofur sodium

Aqueous high-performance size-exclusion chromatographic assay for high-molecular-weight impurities in ceftiofur sodium. Dunn, Michael J.; Hahn, David A. (Upjohn Co., Kalamazoo, MI 49001, USA). J. Chromatogr., 595(1-2), 185-92 (English) 1992. CODEN: JOCRAM. ISSN: 0021-9673. DOCUMENT TYPE: Journal CA Section: 64 (Pharmaceutical Analysis) An aq. high-performance size-exclusion chromatog. assay for high-mol.-wt.Several substances with their cas registry numbers 151-21-3 and 80370-57-6 may be metioned in this study. (HMW) impurities in ceftiofur bulk drug is described. The assay uses a SDS micellar mobile phase to provide complete recovery of the analyte from a glycerylpropyl-bonded silica column. Using 254-nm absorbance detection cor. for relative detector response, the assay provides a linear response and complete recovery of HMW impurities. The relative std. deviation for repeated assay of a single bulk drug lot is 2.5%, with systematic variation of column, mobile phase batch, analyst, lab., instrument and day. The detection limit is 0.03%. .

The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses

All Rights Reserved. The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. Milligan, M.; Kukanich, B.; Beard, W.; Waxman, S. (Department of Clinical Sciences, Analytical Pharmacology Laboratory, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA). Journal of Veterinary Pharmacology and Therapeutics, 29(6), 495-499 (English) 2006 Blackwell Publishing Ltd. CODEN: JVPTD9. ISSN: 0140-7783. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Lidocaine is administered as an i.v. infusion to horses for a variety of reasons, but no study has assessed plasma lidocaine concns. during a 12-h infusion to horses. The purpose of this study was to evaluate the plasma concns. and pharmacokinetics of lidocaine during a 12-h infusion to postoperative horses. A second purpose of the study was to evaluate the in vitro plasma protein binding of lidocaine in equine plasma. Lidocaine hydrochloride was administered as a loading dose. 1.3 Mg/kg over 15 min, then by a const. rate IV infusion, 50 mg/kg/min to six postoperative horses. Lidocaine plasma concns. were measured by a validated high-pressure liq. chromatog. method. One horse experienced tremors and collapsed 5.5 h into the study. The range of plasma concns. during the infusion was 1.21-3.13 mg/mL. Lidocaine plasma concns. were significantly increased at 0.5, 4, 6, 8, 10 and 12 h compared with 1, 2 and 3 h. The in vitro protein binding of lidocaine in equine plasma at 2 mg/mL was 53.06 ± 10.28% and decreased to 27.33 ± 9.In this experiment, several chemicals are used like 80370-57-6 and 73-78-9 72% and 29.52 ± 6.44% when in combination with ceftiofur or the combination of ceftiofur and flunixin, resp. In conclusion, a lower lidocaine infusion rate may need to be administered to horses on long-term lidocaine infusions. The in vitro protein binding of lidocaine is moderate in equine plasma, but highly protein bound drugs may displace lidocaine increasing unbound concns. and the risk of lidocaine toxicity. .